Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery.

Data from permeability profiling using the parallel artificial membrane permeability assay (PAMPA) and cell monolayer (Caco-2 and MDR1-MDCKII) methods were compared for two published compound sets and one in-house set. A majority of compounds in each set correlated (R(2) = 0.76-0.92), indicating the predominance of passive diffusion in the permeation of these compounds. Compounds that did not correlate grouped into two subsets. One subset had higher PAMPA permeability than cell monolayer permeability and consisted of compounds that are subject to secretory mechanisms: efflux or reduced passive diffusion of bases under Caco-2 when run under a pH gradient. The other subset had higher cell monolayer permeability than PAMPA permeability and consisted of compounds that are subject to absorptive mechanisms: paracellular, active transport, or increased passive diffusion of acids under Caco-2 when run under a pH gradient. Given the characteristics of the two methods, these studies suggest how PAMPA and Caco-2 can be synergistically applied for efficient and rapid investigation of permeation mechanisms in drug discovery. During early discovery, all compounds can be rapidly screened using PAMPA at low pH and neutral pH to assess passive diffusion permeability to indicate potential for gastrointestinal and cell assay permeation. During intermediate discovery, selected compounds can be additionally assayed by apical-to-basolateral Caco-2, which, in combination with PAMPA data, indicates susceptibility to additional permeation mechanisms (secretory and absorptive). During mid-to-late discovery, selected candidates can be examined in detail via multiple directional Caco-2 experiments and with transporter inhibitors for complete characterization of permeation mechanisms.

[1]  H. van de Waterbeemd,et al.  Property-based design: optimization of drug absorption and pharmacokinetics. , 2001, Journal of medicinal chemistry.

[2]  M. Machida,et al.  High Throughput Prediction of Oral Absorption: Improvement of the Composition of the Lipid Solution Used in Parallel Artificial Membrane Permeation Assay , 2001, Journal of biomolecular screening.

[3]  Kin-Kai Hwang,et al.  A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. , 2002, European journal of medicinal chemistry.

[4]  Richard A. Morrison,et al.  Evaluation of Biocoat® Intestinal Epithelium Differentiation Environment (3-Day Cultured Caco-2 Cells) as an Absorption Screening Model with Improved Productivity , 1997, Pharmaceutical Research.

[5]  J. Tolan,et al.  MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.

[6]  S. Krämer,et al.  Absorption prediction from physicochemical parameters. , 1999, Pharmaceutical science & technology today.

[7]  G Mannens,et al.  Strategies for absorption screening in drug discovery and development. , 2001, Current topics in medicinal chemistry.

[8]  M. Strafford,et al.  Drug absorption in vitro model: filter-immobilized artificial membranes. 2. Studies of the permeability properties of lactones in Piper methysticum Forst. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[9]  Li Di,et al.  High throughput artificial membrane permeability assay for blood-brain barrier. , 2003, European journal of medicinal chemistry.

[10]  J. Polli,et al.  Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.

[11]  D A Smith,et al.  Pharmacokinetics and metabolism in early drug discovery. , 1999, Current opinion in chemical biology.

[12]  U Norinder,et al.  Experimental and computational screening models for the prediction of intestinal drug absorption. , 2001, Journal of medicinal chemistry.

[13]  P J Sinko Drug selection in early drug development: screening for acceptable pharmacokinetic properties using combined in vitro and computational approaches. , 1999, Current opinion in drug discovery & development.

[14]  D. Thakker,et al.  Efflux Ratio Cannot Assess P-Glycoprotein-Mediated Attenuation of Absorptive Transport: Asymmetric Effect of P-Glycoprotein on Absorptive and Secretory Transport Across Caco-2 Cell Monolayers , 2003, Pharmaceutical Research.

[15]  Kristina Luthman,et al.  Caco-2 monolayers in experimental and theoretical predictions of drug transport1PII of original article: S0169-409X(96)00415-2. The article was originally published in Advanced Drug Delivery Reviews 22 (1996) 67–84.1 , 2001 .

[16]  W R Millington,et al.  Blood-brain barrier transport of caffeine: dose-related restriction of adenine transport. , 1982, Life sciences.

[17]  I. Hidalgo,et al.  Assessing the absorption of new pharmaceuticals. , 2001, Current topics in medicinal chemistry.

[18]  K Gubernator,et al.  Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.

[19]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[20]  Alex Avdeef,et al.  Absorption and drug development , 2003 .

[21]  Arun K Mandagere,et al.  Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. , 2002, Journal of medicinal chemistry.

[22]  H. Vromans,et al.  Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. , 2003, International journal of pharmaceutics.

[23]  D. Ritchie,et al.  The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. , 2001, Current topics in medicinal chemistry.

[24]  Li Di,et al.  Pharmaceutical profiling in drug discovery. , 2003, Drug discovery today.

[25]  Alex Avdeef,et al.  Physicochemical Profiling (Solubility, Permeability and Charge State) , 2001 .

[26]  E. Kerns,et al.  High throughput physicochemical profiling for drug discovery. , 2001, Journal of pharmaceutical sciences.

[27]  Risto Kostiainen,et al.  N-in-One Permeability Studies of Heterogeneous Sets of Compounds Across Caco-2 Cell Monolayers , 2003, Pharmaceutical Research.

[28]  B. Faller,et al.  High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. , 2001, Journal of medicinal chemistry.

[29]  K. Luthman,et al.  Caco-2 monolayers in experimental and theoretical predictions of drug transport , 1996 .

[30]  Matthew D. Troutman,et al.  Novel Experimental Parameters to Quantify the Modulation of Absorptive and Secretory Transport of Compounds by P-Glycoprotein in Cell Culture Models of Intestinal Epithelium , 2003, Pharmaceutical Research.

[31]  K. Terada,et al.  Optimized conditions of bio-mimetic artificial membrane permeation assay. , 2001, International journal of pharmaceutics.

[32]  C. Lipinski Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[33]  B. Testa,et al.  Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques , 2002, Cellular and Molecular Life Sciences CMLS.